FIGURE 10.
Anti-VEGF therapy decreases glioblastoma-induced edema, improving mouse survival. T2-weighted magnetic resonance images (A) and measurement of Ktrans (the vascular permeability-surface area product) (B) in orthotopic glioblastomas after treatment with cediranib, an anti-VEGFR tyrosine kinase inhibitor, show a clear reduction in vessel permeability and hence tumor-associated edema. In this model, cediranib therapy improves animal survival despite having no impact on the growth of primary tumors. [From Kamoun et al. (160). Reprinted with permission. Copyright 2008 American Society of Clinical Oncology. All rights reserved.]